Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation
Open Access Publication
Rights and Permissions
Li, L., Zhang, X., Wang, X. et al. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation. Genome Med 13, 56 (2021). https://doi.org/10.1186/s13073-021-00872-4 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Li, Lijin; Zhang, Xiuli; Wang, Xiaoli; Kim, Samuel W; Herndon, John M; Becker-Hapak, Michelle K; Carreno, Beatriz M; Myers, Nancy B; Sturmoski, Mark A; McLellan, Michael D; Miller, Christopher A; Johanns, Tanner M; Tan, Benjamin R; Dunn, Gavin P; Fleming, Timothy P; Hansen, Ted H; Goedegebuure, S Peter; and Gillanders, William E, "Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation." Genome Medicine. 13, 1. 56 (2021).
This file contains the DNA and amino acid sequences of the polyepitope DNA vaccines created for this study.
13073_2021_872_MOESM2_ESM.xlsx (26 kB)
This file contains Supplementary Table S1 to S4. Table S1. List of HLA-A2-restricted epitopes included in the octamers for optimizing polyepitope DNA vaccine design; Table S2. Selective neoantigens identified in E0771 mouse breast cancer; Table S3. Neoantigens identified in mouse breast cancer cell line 4T1.2; and Table S4. Neoantigens identified in cancer patient GTB16.
13073_2021_872_MOESM3_ESM.pdf (1561 kB)
This file contains Supplementary Methods and Supplementary Figure S1 to S4. Figure S1. Expression of polyepitope constructs and the presentation of antigens. Figure S2. SLP vaccines generated neoepitope-specific CD4 T cell responses. Figure S3. Ubmut-4T1.2 Polyepitope neoantigen DNA vaccine inhibits 4T1.2 tumor growth in vivo. Figure S4. Both MT and WT Lrrc27 peptides bind well to H-2Db.